XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 33 filers reported holding XILIO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $3,776,583 | 4.19% |
| Trustees of Columbia University in the City of New York | 249,635 | $654,044 | 0.96% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $7,229,481 | 0.90% |
| Octagon Capital Advisors LP | 2,425,000 | $6,353,500 | 0.88% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $7,350,182 | 0.76% |
| HARVARD MANAGEMENT CO INC | 416,059 | $1,090 | 0.11% |
| Rock Springs Capital Management LP | 1,440,759 | $3,774,789 | 0.09% |
| Soleus Capital Management, L.P. | 226,941 | $594,585 | 0.07% |
| Artal Group S.A. | 450,000 | $1,179 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 110,481 | $289,460 | 0.01% |
| NWAM LLC | 10,000 | $26,200 | 0.00% |
| Laurion Capital Management LP | 142,900 | $374,398 | 0.00% |
| FIL Ltd | 218,705 | $573,007 | 0.00% |
| Key FInancial Inc | 830 | $2,175 | 0.00% |
| MORGAN STANLEY | 27,016 | $70,782 | 0.00% |
| BlackRock Inc. | 49,211 | $128,933 | 0.00% |
| Citadel Advisors | 13,149 | $34,450 | 0.00% |
| Tower Research Capital LLC (TRC) | 4,394 | $11,512 | 0.00% |
| JPMORGAN CHASE & CO | 2,701 | $7,077 | 0.00% |
| Renaissance Technologies | 20,300 | $53 | 0.00% |
This page lists XILIO THERAPEUTICS INC's shareholders in Q2 2023. To view XILIO THERAPEUTICS INC's shareholder history, click here.